ArticleCancer cell2018
Non-conventional Inhibitory CD4
Article in Cancer cell, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- 7aaRGD - a novel SPP1/integrin signaling-blocking peptide reverses immunosuppression and improves anti-PD-1 immunotherapy outcomes in experimental gliomas.Journal of experimental & clinical cancer research : CR · 2025Article
- Cytokine Storm Related to CD4Immune network · 2024Article
- Dynamic evaluation of blood immune cells predictive of response to immune checkpoint inhibitors in NSCLC by multicolor spectrum flow cytometry.Frontiers in immunology · 2023Article
- Immunotherapy resistance in non-small-cell lung cancer: From mechanism to clinical strategies.Frontiers in immunology · 2023Review
- Functional and molecular characterization of PD1Oncoimmunology · 2022Article
- LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade.Science translational medicine · 2021Article
- Emerging dynamics pathways of response and resistance to PD-1 and CTLA-4 blockade: tackling uncertainty by confronting complexity.Journal of experimental & clinical cancer research : CR · 2021Review
- Characterizing CDK12-Mutated Prostate Cancers.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021Article
- Progress and Challenges of Predictive Biomarkers for Immune Checkpoint Blockade.Frontiers in oncology · 2021Review
- Immune Microenvironment and Response in Prostate Cancer Using Large Population Cohorts.Frontiers in immunology · 2021Article
- Obesity diminishes response to PD-1-based immunotherapies in renal cancer.Journal for immunotherapy of cancer · 2020Article
- Regulatory T cell control of systemic immunity and immunotherapy response in liver metastasis.Science immunology · 2020Article
- Systemic CD4 Immunity as a Key Contributor to PD-L1/PD-1 Blockade Immunotherapy Efficacy.Frontiers in immunology · 2020Review
- Classical Hodgkin's Lymphoma in the Era of Immune Checkpoint Inhibition.Journal of clinical medicine · 2019Review
- Nivolumab-ipilimumab - exploiting the mutation burden of NSCLCs.Nature reviews. Clinical oncology · 2018Article
Corrections and comments
- Erratum for
Authors and funding
16 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.